- Expression profiling of microdissected matched prostate cancer samples reveals CD166/MEMD and CD24 as new prognostic markers for patient survival. Kristiansen, G., Pilarsky, C., Wissmann, C., Kaiser, S., Bruemmendorf, T., Roepcke, S., Dahl, E., Hinzmann, B., Specht, T., Pervan, J., Stephan, C., Loening, S., Dietel, M., Rosenthal, A. J. Pathol. (2005)